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Aim: Coronary angiography is indicated in many patients with known or suspected angina for 
the investigation of coronary artery disease (CAD). However, up to half of patients with 
symptoms of ischaemia have no obstructive coronary arteries (INOCA). This large subgroup 
includes patients with suspected microvascular angina (MVA) and/or vasospastic angina 
(VSA). Clinical guidelines relating to the management of patients with INOCA are limited.  
Uncertainty regarding the diagnosis of patients with INOCA presents a health economic 
challenge, both in terms of healthcare resource utilisation and of quality-of-life impact on 
patients.  
Methods: A cost-effectiveness analysis of the introduction of stratified medicine into the 
invasive management of INOCA, based on clinical and resource-use data obtained in the 
CorMicA trial, from a UK NHS perspective. The intervention included an invasive diagnostic 
procedure (IDP) of coronary vascular function during coronary angiography to define clinical 
endotypes to target with linked medical therapy.  Outcomes of interest were mean total cost 
and QALY gain between treatment groups, and the incremental cost-effectiveness ratio. We 
undertook probabilistic sensitivity and scenario analyses. 
Results: The incremental cost per QALY gained at 12 months was £4,500 (£2,937, £33,264). 
Compared with a willingness-to-pay (WTP) threshold of £20,000 per QALY, the use of the IDP 
test is cost-effective. At this WTP threshold there is a 96% probability of the IDP being cost-
effective, based on the uncertainty described by bootstrap analysis. 
Conclusions: The burden of INOCA, particularly in women, is known to be significant. These 
findings provided new evidence to inform this unmet clinical need. 
 












 What is already known about this subject? 
Coronary angiography is routinely performed in patients with signs or symptoms of angina. 
However, up to half of patients with signs and/or symptoms of ischaemia have no obstructive 
coronary arteries (INOCA) presenting a diagnostic and therapeutic challenge for clinicians. 
This large subgroup includes patients with suspected microvascular angina and/or 
vasospastic angina endotypes. The burden of INOCA, particularly in women, is known to be 
significant. 
 What does this study add? 
Our cost-effectiveness analysis found that the use of adjunctive testing to identify and tailor 
treatment based on patient endotype is associated with an increase in both mean cost per 
patient and quality-adjusted life years (QALYs) gained. With an incremental cost-effectiveness 
ratio of approximately £4,500, such a clinical strategy would be highly cost-effective in a UK 
setting. 
 How might this impact on clinical practice? 
Adjunctive coronary testing would allow for the stratification of this hitherto undifferentiated 
subpopulation and the targeting of linked medical therapy. This would bring immediate 
benefits to patients in terms of an improvement in quality of life. The reduction is disease 















Coronary angiography is routinely performed in patients with suspected angina. 
Approximately four million elective coronary angiograms are performed each year in Europe 
and the United States (1, 2).  However, up to half of patients with signs and/or symptoms of 
ischaemia have no obstructive coronary arteries (INOCA) presenting a diagnostic and 
therapeutic challenge for clinicians (2). This large subgroup includes patients with suspected 
microvascular angina (MVA) and/or vasospastic angina (VSA) (3). Coronary angiography is 
insensitive in visualising the micro-vessels (4). Coronary angiography is also insensitive for 
coronary reactivity and a patient’s susceptibility to vasospasm. The rationale for adjunctive 
coronary vascular function testing, in the form of an interventional diagnostic procedure 
(IDP) is as follows. Firstly, coronary angiography does not exclude a disorder of coronary 
vascular function, such as those relating to vasomotion or microcirculation (3). Secondly, 
adjunctive coronary testing allows for the stratification of this hitherto undifferentiated 
subpopulation (3). This is important because discrimination between microvascular angina, 
vasospastic angina, both, or neither, allows for specific and distinct treatment regimes. 
Finally, adjustive coronary function testing provides both patients and their physicians with 
prognostic information. Clinical guidelines relating to the management of patients with 
INOCA are limited by a lack of randomised controlled trials (5). 
The uncertainty regarding the diagnosis of patients with INOCA presents a health economic 
challenge, both in terms of healthcare resource utilisation and of quality-of-life impact on 
patients. Patients with INOCA who remain undiagnosed are liable to re-present at primary or 
secondary care. This may result in additional GP consultations, outpatient cardiologist visits, 












The British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) trial was a 
randomised, controlled, developmental clinical trial of stratified medicine in patients with 
known or suspected angina undergoing clinically-indicated coronary angiography in the 
National Health Service.  
The CorMicA study design and main trial results have been described in detail elsewhere (3, 
7, 8). In summary, 391 patients with angina undergoing invasive coronary angiography 
(standard care) were recruited between November 2016 and December 2017. 151 patients 
without angiographically obstructive CAD were randomised to either the intervention group 
(standard care, plus IDP-guided stratified medical therapy and cardiac rehabilitation) (n=76) 
or control group (standard care, plus medical therapy and cardiac rehabilitation) (n=75). The 
IDP consisted of guidewire-based assessment of coronary flow reserve, index of 
microcirculatory resistance, fractional flow reserve, followed by vasoreactivity testing with 
acetylcholine. Following the IDP, clinicians were able to update their diagnosis, if indicated, 
based on this additional information, and to tailor patient medical therapy and cardiac 
rehabilitation accordingly. The intervention resulted in a mean improvement of 13.6 units in 
the Seattle Angina Questionnaire summary score (primary outcome) at 12 months (95% CI: 
7.3 to 19.9; p<0.001).  
The aim of this study was to undertake a cost-effectiveness analysis of the BHF CorMicA trial, 
using resource use and quality of life data from the trial, to estimate the potential cost-


















An economic evaluation was undertaken using clinical and resource use data obtained from 
the CorMicA feasibility trial and from the wider literature. We employed the standard 
methodology for an economic evaluation alongside a clinical trial (9). A conceptual model 
was designed and presented to illustrate the patient pathway and to facilitate interpretation 
of the trial data.  
 
2.2 Study perspective 
The economic evaluation was undertaken from the perspective of the National Health Service 
(NHS) of the United Kingdom (U.K.) for cost year 2018/19, adhering to contemporary practice 
guidelines and the NICE reference case (10). 
 
2.3 Time horizon 
The economic evaluation estimated the cost and quality-of-life (QALY) gained, by trial arm, 
over the one-year time horizon of the BHF CorMicA trial. 
 
2.4 Discount rate 
The discounting of NHS costs and health outcomes was not necessary for the economic 
evaluation as the CorMicA trial was limited to a one-year time horizon.  
 
2.5 Conceptual model of the CorMicA trial 
We developed a conceptual model to illustrate the clinical pathway for each clinical strategy 















The conceptual model begins with a patient with signs and/or symptoms of angina who has 
received coronary angiography and are subsequently diagnosed with no obstructive coronary 
artery disease (NOCAD). At this point, the standard care procedure would end. 
In line with the CorMicA trial, patients may then receive either a “sham test” (control group) 
or the IDP (intervention group). In the control group branch of the model, patients receive 
the IDP but the results are not disclosed to the attending clinicians who are therefore blind to 
the IDP results. Patients then receive the standard of care for patients with signs and/or 
symptoms of angina but no CAD.  
In the intervention group branch of the conceptual model, patients receive the IDP. 
Physicians were informed of the IDP results and were able to revise their initial diagnosis, 
which was based on the angiogram and all of the other available clinical information (e.g. 
prior non-invasive test results, medical history). Based on this new information, patients 
could either receive a diagnosis of positive or negative (for the purposes of the conceptual 
model, a positive diagnosis for any of the MVA or VSA endotypes is categorised as “positive”). 
Patients were then subsequently offered alternative medication and/or lifestyle modification 
advice depending on their revised diagnosis. If patients were subsequently diagnosed as 
“negative”, anti-anginal therapies were discontinued. 
 












Resource use estimates were obtained from the CorMicA trial, published literature and 
expert opinion (the CorMicA clinical trial team) (Table 1). Medication, participation in a 
cardiac rehabilitation programme, and IDP costs were included in the base case analysis. 
Anginal medications were measured at baseline, six months and 12 months in the trial. Based 
on these data, we measured the proportion of the year a patient spent on each medication. 
We then estimated the proportion of the year spent on each mediation by the mean patient 
in each trial arm. Relevant unit costs were adjusted to annual costs for each medication and 
attached to the time spent on medication to obtain the mean cost of medication by trial arm. 
The cost of the IDP was included for all patients in the intervention group only. The unit cost 
of a cardiac rehabilitation cost was attached to the number of patients reporting attendance 
at a cardiac rehabilitation programme at 12 months. Medication cost, IDP test cost and 
cardiac rehabilitation programme cost were combined to obtain a mean total patient cost by 
trial arm. 
All unit costs were collected or converted into UK pounds sterling (£) for the price year 
2018/19. Prices are also presented for 2018/19 Euros. Unit costs were collected from routine 
sources such as the British National Formulary (11), Personal Social Services Resource Unit 
(PSSRU) (12) and NHS Reference Costs (13). Some unit costs were obtained from NHS 
Reference Costs or from local sources (NHS Golden Jubilee National Hospital) (Table 1). 
 
Table 1: Resource use item and unit cost 
Medication Dose Cost per pill Cost per year Source 
Statin 40mg daily £0.03 £11 BNF 
Beta-blocker 2.5mg daily £0.03  £11 BNF 
Calcium channel 
blocker 
120mg daily £0.03 £29 BNF 
Isosorbide 
mononitrate 
20mg daily £0.05 £36 BNF 
Nicorandil 40mg daily £0.06 £45  BNF 












Ranolazine 1000mg daily £0.82 £595  BNF 
Ivabradine 14mg daily £0.12 £90  BNF 
Nitroglycerin (spray) 1 bottle per 3 months £12 £12  BNF 
IDP (test) Resource use  Unit cost Source 
Catheter lab time Per hour   £400  NHS Golden Jubilee 
costing records Acetylcholine test Per vial  £7  BNF 




Per guidewire  £350  NHS Golden Jubilee 
costing records Other costs Resource use  Unit cost Source 
Cardiac rehabilitation 
programme 
Per programme  £279  NHS Reference 
costs 
Re-presentation 
package of care 
(scenario analysis 
only) 
Resource use  Unit cost Source 
Coronary angiogram Per test  £1,379  NHS Reference 
costs GP appointment Per appointment  £37  PSSRU 2018 
Cardiology outpatient 
appointment 
Per appointment  £134  PSSRU 2018 
Blood test, U&E renal 
test, lipids test, Hba1c 
test 
Per test (one of each 
test) 
 £7  NHS Reference 
costs 
1 The diagnostic coronary guidewire used in this study was PressureWire X (Abbott Vascular, Santa Clara, CA). 
2 One third of patients in the CorMicA trial had a guidewire in place prior to IDP. For this reason, the cost of a guidewire is applied to two 
thirds of patients in the intervention group (rather than every patient). 
 
2.7 Quality-of-life analysis 
Quality-of-life (QoL) outcomes were based on the EuroQoL-5D (EQ-5D-5L) questionnaire and 
collected at baseline, 6 and 12 months in the CorMicA trial participants and expressed as 
health utility indices. 
Quality adjusted-life years were calculated using the area-under-the-curve method (AUC) 
(14). The AUC was estimated for each individual in the trial by weighting the time between 
EQ-5D health utility measurement in the trial by their health utility value over that time 
period. 
 












Mean cost and QALY gain per patient, by trial arm, was estimated by using a generalized 
linear model (GLM) and adjusting for potential confounding factors (age, sex, BMI and trial 
arm). The appropriate family for the GLM was selected based on the results of the modified 
Park’s test. Our final cost model was based on the log link and gamma family and our final 
QALY model was based on the identity link and Gaussian family. There were few missing 
resource-use or EQ-5D data in the CorMicA trial (≤5%). Where missing data existed, multiple 
imputation by chained equations (MICE) was used to impute missing data (15). All analyses 
were conducted using Stata 14 (StataCorp). 
The outcomes of interest are mean costs, mean quality adjusted life year (QALY) gained, and 
the incremental cost-effectiveness ratio (ICER), expressed as the cost per QALY. The 
estimated ICER is compared with a willingness-to-pay (WTP) threshold of £20,000 per QALY 
gained, which is a commonly accepted cost-effectiveness threshold used by the National 
Institute for Health and Care Excellence (NICE) in the United Kingdom.  
 
2.9 Sensitivity analysis 
The distribution of incremental mean costs and QALYs produced by a bootstrap analysis were 
presented on the cost-effectiveness plane. Cost-effectiveness acceptability curves (CEACs) 
were used to present the uncertainty in the decision regarding the most cost-effective 
option, over a variety of monetary willingness to pay thresholds. 
 
2.10 Scenario analyses 
Data on the number of previous coronary angiograms among patients enrolled in the 
CorMicA trial indicated that approximately one third (51 out of 151) of patients had “at least 












involved in both the trial, and in the routine care of this patient population, which suggests 
that patients with signs and symptoms of angina, but no obstructive coronary artery disease 
are liable to re-present in primary or secondary care.  
Given the large potential cost associated with these re-representations, we modelled the 
impact of IDP testing on reducing the proportion of patients re-presenting to primary and 
secondary care with signs/symptoms of angina following coronary angiography. To 
implement this scenario in the model, we assumed that patients diagnosed as negative for 
microvascular or vasospastic angina following IDP testing did not re-present with suspected 
angina, and that a proportion of patients in the control group do re-present. For patients who 
re-present, we proposed a typical “package of care” associated with a re-presentation, 
including: one coronary angiogram, three GP appointments, two cardiology outpatient 
appointments and standard care diagnostic tests (U&E, lipids, Hba1c). In the CorMicA trial, 
data on repeat visits to primary care or hospital outpatient clinics were not prospectively 
captured, as such there is some uncertainty as to the true impact of adjunctive functional 
test in a real-world setting. 
The unit costs associated with these resources are given in Table 1. Based on the utilisation of 
each resource required, we estimated a cost associated with an angiogram package of care of 
£1,786. We estimated the impact on the mean cost per patient in the control group if one 
third, one fifth, and one tenth of patients re-present in primary care.  
 
2.11 Ethical approval 














2.12 Patient and Public Involvement 
CorMicA researchers engaged with the patient population (service users) and the British 
Cardiovascular Care Partnership in the design of the CorMicA trial. 
 
3. RESULTS 
The baseline characteristics of the patient population are given in Table 2. The median age in 
the study was 61 years old, with the majority of the study participants being female (73.5%). 
There was a high prevalence of cardiovascular risk factors. Participants had impaired quality 
of life at baseline, as reflected by EQ-5D-5L health status (mean: 0.60, s.d.: 0.29) and SAQ 
Summary Score (mean 50.8, s.d.: 18.1). 
 
Table 2: Baseline demographic and clinical characteristics of the CorMicA patient 
population 
 All (n=151) Control (n=76) Intervention (n=75) 
Age 61 (53, 68) 60 (53, 68) 62 (54, 69) 
Female 111 (73.5%) 58 (76.3%) 53 (70.7%) 
BMI (kg/m2) 29.7 (25.6, 34.7) 29.7 (25.6, 34.0) 29.6 (25.7, 34.8) 
Smoker 27 (17.9%) 14 (18.4%) 13 (17.3%) 
Previous myocardial infarction 24 (15.9%) 13 (17.1%)  11 (14.7%) 
Previous stroke or TIA 20 (13.2%) 13 (17.1%) 7 (9.3%) 
Diabetes mellitus 29 (19.2%) 15 (19.7%) 14 (18.7%) 
Dyslipidaemia 120 (79.5%) 61 (80.3%) 59 (78.7%) 
Family history of CVD 105 (69.5%) 51 (67.1%) 54 (72.0%) 
Predicted 10-year CHD risk* 18.6 (10.6, 31.4) 18.1 (9.7, 27.9) 19.0 (11.9, 38.9) 
Aspirin 
 
131 (86.8%) 67 (88.2%) 64 (85.3%) 
Beta-blocker 101 (66.9%) 51 (67.1%) 50 (66.7%) 
Calcium channel blocker 52 (34.4%) 28 (36.8%) 24 (32.0%) 
Nitrates 
Statin 
71 (47.0%) 38 (50.0%) 33 (44.0%) 
Statin 126 (83.4%) 66 (86.8%)  60 (80.0%) 
Nicorandil 26 (17.2%) 15 (19.7%) 11 (14.7%) 
ACE inhibitor or angiotensin receptor 
blocker 
68 (45.0%) 35 (46.1%) 33 (44.0%) 
Total cholesterol (mmol/L) 3.55 (0.98) 3.57 (1.06) 3.52 (0.90) 
HDL cholesterol (mmol/L) 1.2 (0.4) 1.2 (0.3) 1.2 (0.4) 
Baseline Angina Questionnaire: non-
angina 












Definite (typical) angina 97 (64.2%) 42 (55.3%) 55 (73.3%) 
Probable (atypical) angina 54 (35.8%) 34 (44.7%) 20 (26.7%) 
Seattle Angina Questionnaire    
Seattle Angina (summary) score 50.8 (18.1) 49.0 (17.2) 52.6 (18.9) 
Angina limitation 52.1 (24.4) 52.4 (24.3) 51.9 (24.7) 
Angina stability 44.7 (24.4) 41.4 (25.3) 48.0 (23.2) 
Angina frequency 59.3 (23.5) 54.9 (21.3) 63.7 (25.0) 
Angina treatment satisfaction 81.9 (19.5) 81.9 (20.0) 81.8 (19.1) 
Angina quality of life 40.9 (21.7) 39.7 (21.7) 42.1 (21.9) 
Quality of life (EQ5D-5L)    
Index value 0.60 (0.29) 0.58 (0.30) 0.62 (0.28) 
VAS score 66.3 (20.5) 67.9 (21.1) 64.6 (19.8) 
Stress electrocardiogram (performed) 95 (62.9%) 46 (60.5%) 49 (65.3%) 
Negative (normal) 13 (13.7%) 6 (13.0%) 7 (14.3%) 
Inconclusive 37 (39.0%) 18 (39.1%) 19 (38.8%) 
Abnormal 45 (47.4%) 22 (47.8%) 23 (46.9%) 
Radionuclide myocardial perfusion 
(performed) 
58 (38.4%) 30 (39.5%) 28 (37.3%) 
Negative or inconclusive 28 (48.3%) 17 (56.7%) 11 (39.3%) 
Abnormal 30 (51.7%) 13 (43.3%) 17 (60.7%) 
Values are median (interquartile range), n (%), or mean +/- SD. *ASSIGN risk score. 
 
3.1 Resource use results 
The mean time spent on medication was greater in seven out of the nine medications 
included in the intervention group, compared with the control group (Table 3). Thirty 
patients (40%) reported attending a cardiac rehabilitation programme in the intervention 
group, compared with 12 patients (16%) in the control group. All patients in the intervention 
group received the IDP test, compared with none in the control group. 
 
Table 3: Mean resource use (proportion and 95% confidence intervals) and mean cost (£), 
by trial arm 
 Standard care with 
control 




Standard care with 
stratified medicine  Resource use (proportion and 95% CIs) Mean cost per patient (£) 
Medication       
Statin 0.59 (0.50, 0.69) 0.79 (0.70, 0.89) 6.81 (5.77, 7.85) 9.157 (8.10, 10.21) 
Beta-blockers 0.52 (0.44, 0.60) 0.58 (0.49, 0.66) 5.99 (5.04, 6.94) 6.67 (5.711, 7.63) 
Nitroglycerin 0.34 (0.26, 0.41) 0.79 (0.71, 0.86) 4.11 (3.19, 5.02) 9.48 (8.55, 10.40) 
Nicorandil 0.11 (0.04, 0.17) 0.15 (0.08, 0.21) 5.13 (2.18, 8.07) 6.80 (3.82, 9.79) 













*p-value (difference in proportion) = 0.001 
 
3.2 Cost results 
The total mean cost per patient in the control arm of the trial was £103 and was comprised 
solely of medication and cardiac rehabilitation programme costs (Table 4). The total mean 
cost per patient in the intervention group was £568 and was comprised of the costs of the 
IDP, medication and cardiac rehabilitation programme. This equates to an incremental cost of 
£465 at 12 months associated with the intervention group. 
 
3.3 Quality-of-life results 
We estimated the mean QALY gain using the AUC approach. Patients in the control group had 
a mean QALY of 0.548 at 12 months, compared with 0.652 in the intervention group (Table 
4). This equates to a mean QALY gain of 0.104 at 12 months in patients in the intervention 
group. 
 
3.4 Cost-effectiveness results 
The incremental cost per QALY gained at 12 months was £4,500 (£2,937, £33,264) (Table 4). 
Compared with a willingness-to-pay (WTP) threshold of £20,000 per QALY, this suggest that 
Ranolazine 0.02 (0.00, 0.04) 0.01 (0.00, 0.03) 12.50 (0.00, 
28.41) 
7.28 (0.00, 23.40) 
Ivabradine 0.02 (0.00, 0.04) 0.01 (0.00, 0.03) 1.79 (0.00, 3.70) 0.90 (0.00, 2.83) 
CCB 0.20 (0.11, 0.29) 0.42 (0.33, 0.52) 6.04 (3.32, 8.76) 12.60 (9.84, 15.35) 
Isonitrate 0.26 (0.17, 0.35) 0.34 (0.25, 0.43) 9.59 (6.33, 12.84) 12.56 (9.27, 15.86) 
Cardiac rehabilitation programme   
 12 (16%)* 30 (40%)* 43.53 (16.20, 
70.66) 
112.44 (86.15, 
141.33) IDP test      
Catheter lab time 0 20 minutes 0 133 
Acetylcholine test 0 1 vial 0 7  


















the use of stratified medicine with the IDP and linked medical therapy is a cost-effective use 
of resources. 
 
Table 4: Mean costs, mean QALYs, and cost-effectiveness ratio (and 95% confidence 
intervals) for the intervention group and control group 




IDP cost Total cost 
Control group £61 (40, 81) £44 (21, 67) N/A £103 (77, 128) 
Intervention 
group 
£80 (62, 98) £112 (80, 143) £376 (€410) £568 (419, 714) 
Difference  £19 (-8, 46) £68 (29, 107) £376 (€410) £465 (397, 530) 
QALY analysis   Mean QALY 95% confidence 
interval 
Control group   0.548 0.488, 0.609 
Intervention 
group 
  0.652 0.589, 0.714 
Difference   0.104 0.018, 0.190 







Control group     
Intervention 
group 





3.5 Sensitivity analysis 
A visual illustration of the uncertainty surrounding the mean incremental cost and QALY gain 
in the intervention group over 1,000 iterations of bootstrap analysis plotted on the cost-
effectiveness plane is presented in Figure 2. The x-axis represents the incremental QALY gain, 
and the y-axis represents the incremental cost, associated with the intervention group 
compared with the control group. The majority of the cost and QALY estimates are placed in 
the north-east quadrant of the cost-effectiveness plane, suggesting that the use of the 















The probability of the intervention being cost-effective, compared with the control group, is 
given for alternative willingness-to-pay for QALY gain thresholds in Figure 3. At a WTP 
threshold of £20,000 per QALY gained, there is a 96% probability of the intervention being 




3.6 Scenario analysis 
We explored the impact on our cost-effectiveness results of making an assumption regarding 
the number of re-presentations that might be avoided as result of the introduction of 
stratified medicine involving IDP testing with linked therapy. Including the cost of re-
presentations has the impact of increasing the cost-effectiveness of the intervention, 
compared with the base-case scenario (Table 5). A reduction in the proportion of patients 
who re-present for angiograms has the impact of reducing the cost-effectiveness associated 
with the intervention. However, for all re-presentation scenarios considered, the intervention 
was still either highly cost-effective or cost-saving. 
 
Table 5: Sensitivity analysis results: cost-effectiveness results including potential re-
presentations avoided 




































Control group £460 0.548    
Intervention 
group 






Control group £282 0.548    
Intervention 
group 














Our cost-effectiveness analysis of the CorMicA trial found that the introduction of stratified 
medicine, including an adjunctive interventional diagnostic procedure for the management of 
patients with signs and symptoms of angina when obstructive coronary artery disease is 
excluded by the angiogram, is likely to be associated with an increase in patient quality-of-life 
and an increase in health-related resource use over the trial period. With a mean incremental 
cost of £465 and incremental QALY gain of 0.104 per patient, we estimate an incremental 
cost-effectiveness ratio of £4,500. Hence, our results find that stratified medicine in this 
patient population and setting is likely to be cost-effective in a UK setting.  
The CorMicA trial participants had substantial impairment in quality of life at baseline, as 
reflected by EQ-5D-5L health status (17) and SAQ Summary Score (18, 19). Our results have 
provided insights into the mechanisms of treatment effect. We have found that that the 
benefit is determined to an appreciable extent by changes in medication aligned to the 
endotype. Other factors, such as participation in cardiac rehabilitation and control of vascular 
risk factors, are also relevant. The potential reduction in repeat coronary angiogram 
procedures (and related cost saving) in patients with persisting symptoms of angina, as a 
result of introducing IDP testing, has the potential to increase the cost-effectiveness of IDP 
testing. 
The burden of INOCA, particularly in women, is known to be significant (20). Three quarters 
of the trial participants were female. Cardiology trials generally enrol more males than 
females, not least since coronary artery disease predominately affects men. Accordingly, 
CorMicA provides new data that is particularly relevant to heart disease in women. 
To date, there are no comparable studies. CorMicA was the first, randomised controlled trial 












half of all-comers, presents an unmet clinical need, that are usually discounted from clinical 
trials. It is noteworthy that the health-related quality of life, as measured by EQ5D-5L and 
SAQ scores, were lower in CorMicA (patients with NOCAD), compared with recent clinical 
trials of patients with obstructive coronary artery disease (ORBITA (18), ISCHEMIA (19)).  
This is the first study to investigate the health-related resource use implications of the 
introduction of adjunctive coronary function testing in patients with INOCA.  
There is no long-term evidence on the re-presentation rate of patients with signs and 
symptoms of angina with a negative diagnosis of macrovascular angina following coronary 
angiography. In the CorMicA trial population, one in three patients had a history of prior 
coronary angiography indicating a persisting health burden and related demand on primary 
and secondary care. This can be explained by the limitations of the standard, angiography-
guided care to reduce the health need of affected patients. The International Coronary 
Microvascular Angina (iCorMicA) trial which will randomise 1500 patients in Europe, is 
designed to address this evidence gap in multiple centres in different healthcare settings 
(ClinicalTrials.gov Identifier: NCT04674449). However, scenario analysis of our results 
suggests that, even when varying the proportion of patients expected to re-present for 
angiograms, stratified medicine involving the IDP test is still highly likely to represent a cost-
effective use of resources. Indeed, even if no patients re-present (base case results), this 
clinical strategy is still likely to be cost-effective. In addition, our analysis included only costs 
attributable to the UK NHS healthcare system – we did not attempt to capture non-
healthcare system costs, such as productivity costs (both absenteeism and presenteeism). 














The diagnostic management of stable chest pain is also evolving. CT coronary angiography 
(CTCA) has very high sensitivity for coronary artery disease and moderately high specificity 
for discriminating obstructive lesions. CTCA is recommended as the first line test in patients 
presenting with stable chest pain in the National Health Service (22) and is increasingly 
adopted in Europe (23), including the United States (24). The functional significance of 
coronary artery lesions may be assessed using adjunctive FFR-CT, however, since CTCA does 
not provide information on ischaemia (the metabolic consequence of angina), the 
implications of this strategy for patients with INOCA are uncertain. The CorCTCA trial is 
prospectively assessing this evidence gap and a health economic analysis will also be 
undertaken (25). 
The quality-of-life improvement in the intervention group is believed to be a result of both 
pharmacological and non-pharmacological factors, including participation in cardiac 
rehabilitation. The IDP identifies INOCA in patients who otherwise would have received a 
false negative diagnosis and ineffective treatment. Our results suggest that the benefit is 
determined to an appreciable extent by changes in medication aligned to the endotype. 
Other factors, such as participation in cardiac rehabilitation and control of vascular risk 
factors, are also relevant. Further research aimed at understanding the mechanism by which 
this quality-of-life increase is generated seems warranted. 
 
5. CONCLUSION 
We undertook an economic evaluation of the CorMicA trial to estimate the cost-effectiveness 
of introducing stratified medicine using an adjunctive interventional diagnostic procedure 
with mechanistically-targeted medical therapy for the management of patients with signs 












likely to be cost-effective. The economic benefits of IDP testing increase further if we 
incorporate plausible assumptions regarding repeat angiograms in patients with persistent 
sign/symptoms of angina. 
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Table 1: Resource use item and unit cost 
Medication Dose Cost per pill Cost per year Source 
Statin 40mg daily £0.03 £11 BNF 
Beta-blocker 2.5mg daily £0.03  £11 BNF 
Calcium channel 
blocker 
120mg daily £0.03 £29 BNF 
Isosorbide 
mononitrate 
20mg daily £0.05 £36 BNF 
Nicorandil 40mg daily £0.06 £45  BNF 
ACE inhibitor 10mg daily £0.07  £27  BNF 
Ranolazine 100mg daily £0.82 £595  BNF 
Ivabradine 14mg daily £0.12 £90  BNF 
Nitroglycerin (spray) 1 bottle per 3 months £12 £12  BNF 
IDP (test) Resource use  Unit cost Source 
Catheter lab time Per hour   £400  NHS Golden Jubilee 
costing records Acetylcholine test Per vial  £7  BNF 




Per guidewire  £350  NHS Golden Jubilee 
costing records Other costs Resource use  Unit cost Source 
Cardiac rehabilitation 
programme 
Per programme  £279  NHS Reference 
costs 
Re-presentation 
package of care 
(scenario analysis 
only) 
Resource use  Unit cost Source 
Coronary angiogram Per test  £1,379  NHS Reference 
costs GP appointment Per appointment  £37  PSSRU 2018 
Cardiology outpatient 
appointment 
Per appointment  £134  PSSRU 2018 
Blood test, U&E renal 
test, lipids test, Hba1c 
test 
Per test (one of each 
test) 
 £7  NHS Reference 
costs 
1 The diagnostic coronary guidewire used in this study was PressureWire X (Abbott Vascular, Santa Clara, CA). 
2 One third of patients in the CorMicA trial had a guidewire in place prior to IDP. For this reason, the cost of a guidewire is applied to two 














Table 2: Baseline demographic and clinical characteristics of the CorMicA patient 
population 
 All (n=151) Control (n=76) Intervention (n=75) 
Age 61 (53, 68) 60 (53, 68) 62 (54, 69) 
Female 111 (73.5%) 58 (76.3%) 53 (70.7%) 
BMI (kg/m2) 29.7 (25.6, 34.7) 29.7 (25.6, 34.0) 29.6 (25.7, 34.8) 
Smoker 27 (17.9%) 14 (18.4%) 13 (17.3%) 
Previous myocardial infarction 24 (15.9%) 13 (17.1%)  11 (14.7%) 
Previous stroke or TIA 20 (13.2%) 13 (17.1%) 7 (9.3%) 
Diabetes mellitus 29 (19.2%) 15 (19.7%) 14 (18.7%) 
Dyslipidaemia 120 (79.5%) 61 (80.3%) 59 (78.7%) 
Family history of CVD 105 (69.5%) 51 (67.1%) 54 (72.0%) 
Predicted 10-year CHD risk 18.6 (10.6, 31.4) 18.1 (9.7, 27.9) 19.0 (11.9, 38.9) 
Aspirin 
 
131 (86.8%) 67 (88.2%) 64 (85.3%) 
Beta-blocker 101 (66.9%) 51 (67.1%) 50 (66.7%) 
Calcium channel blocker 52 (34.4%) 28 (36.8%) 24 (32.0%) 
Nitrates 
Statin 
71 (47.0%) 38 (50.0%) 33 (44.0%) 
Statin 126 (83.4%) 66 (86.8%)  60 (80.0%) 
Nicorandil 26 (17.2%) 15 (19.7%) 11 (14.7%) 
ACE inhibitor or angiotensin receptor 
blocker 
68 (45.0%) 35 (46.1%) 33 (44.0%) 
Total cholesterol (mmol/L) 3.55 (0.98) 3.57 (1.06) 3.52 (0.90) 
HDL cholesterol (mmol/L) 1.2 (0.4) 1.2 (0.3) 1.2 (0.4) 
Baseline Angina Questionnaire: non-
angina 
   
Definite (typical) angina 97 (64.2%) 42 (55.3%) 55 (73.3%) 
Probable (atypical) angina 54 (35.8%) 34 (44.7%) 20 (26.7%) 
Seattle Angina Questionnaire    
Seattle Angina (summary) score 50.8 (18.1) 49.0 (17.2) 52.6 (18.9) 
Angina limitation 52.1 (24.4) 52.4 (24.3) 51.9 (24.7) 
Angina stability 44.7 (24.4) 41.4 (25.3) 48.0 (23.2) 
Angina frequency 59.3 (23.5) 54.9 (21.3) 63.7 (25.0) 
Angina treatment satisfaction 81.9 (19.5) 81.9 (20.0) 81.8 (19.1) 
Angina quality of life 40.9 (21.7) 39.7 (21.7) 42.1 (21.9) 
Quality of life (EQ5D-5L)    
Index value 0.60 (0.29) 0.58 (0.30) 0.62 (0.28) 
VAS score 66.3 (20.5) 67.9 (21.1) 64.6 (19.8) 
Stress electrocardiogram (performed) 95 (62.9%) 46 (60.5%) 49 (65.3%) 
Negative (normal) 13 (13.7%) 6 (13.0%) 7 (14.3%) 
Inconclusive 37 (39.0%) 18 (39.1%) 19 (38.8%) 
Abnormal 45 (47.4%) 22 (47.8%) 23 (46.9%) 
Radionuclide myocardial perfusion 
(performed) 
58 (38.4%) 30 (39.5%) 28 (37.3%) 
Negative or inconclusive 28 (48.3%) 17 (56.7%) 11 (39.3%) 















Table 3: Mean resource use (proportion and 95% confidence intervals) and mean cost (£), 
by trial arm 
*p-value (difference in proportion) = 0.001 
 
  
 Standard care with 
control 




Standard care with 
stratified medicine  Resource use (proportion and 95% CIs) Mean cost per patient (£) 
Medication       
Statin 0.59 (0.50, 0.69) 0.79 (0.70, 0.89) 6.81 (5.77, 7.85) 9.157 (8.10, 10.21) 
Beta-blockers 0.52 (0.44, 0.60) 0.58 (0.49, 0.66) 5.99 (5.04, 6.94) 6.67 (5.711, 7.63) 
Nitroglycerin 0.34 (0.26, 0.41) 0.79 (0.71, 0.86) 4.11 (3.19, 5.02) 9.48 (8.55, 10.40) 
Nicorandil 0.11 (0.04, 0.17) 0.15 (0.08, 0.21) 5.13 (2.18, 8.07) 6.80 (3.82, 9.79) 
ACE 0.36 (0.26, 0.46) 0.51 (0.40, 0.61) 9.89 (7.22, 12.56) 13.69 (10.98, 
16.40) Ranolazine 0.02 (0.00, 0.04) 0.01 (0.00, 0.03) 12.50 (0.00, 
28.41) 
7.28 (0.00, 23.40) 
Ivabradine 0.02 (0.00, 0.04) 0.01 (0.00, 0.03) 1.79 (0.00, 3.70) 0.90 (0.00, 2.83) 
CCB 0.20 (0.11, 0.29) 0.42 (0.33, 0.52) 6.04 (3.32, 8.76) 12.60 (9.84, 15.35) 
Isonitrate 0.26 (0.17, 0.35) 0.34 (0.25, 0.43) 9.59 (6.33, 12.84) 12.56 (9.27, 15.86) 
Cardiac rehabilitation programme   
 12 (16%)* 30 (40%)* 43.53 (16.20, 
70.66) 
112.44 (86.15, 
141.33) IDP test      
Catheter lab time 0 20 minutes 0 133 
Acetylcholine test 0 1 vial 0 7  


















Table 4: Mean costs, mean QALYs, and cost-effectiveness ratio (and 95% confidence 
intervals) for the intervention group and control group 




IDP cost Total cost 
Control group £61 (40, 81) £44 (21, 67) N/A £103 (77, 128) 
Intervention 
group 
£80 (62, 98) £112 (80, 143) £376 (€410) £568 (419, 714) 
Difference  £19 (-8, 46) £68 (29, 107) £376 (€410) £465 (397, 530) 
QALY analysis   Mean QALY 95% confidence 
interval 
Control group   0.548 0.488, 0.609 
Intervention 
group 
  0.652 0.589, 0.714 
Difference   0.104 0.018, 0.190 







Control group     
Intervention 
group 

















Table 5: Sensitivity analysis results: cost-effectiveness results including potential re-
presentations avoided 
















Control group £698 0.548    
Intervention 
group 






Control group £460 0.548    
Intervention 
group 






Control group £282 0.548    
Intervention 
group 
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 What is already known about this subject? 
Coronary angiography is routinely performed in patients with signs or symptoms of angina. 
However, up to half of patients with signs and/or symptoms of ischaemia have no obstructive 
coronary arteries (INOCA) presenting a diagnostic and therapeutic challenge for clinicians. 
This large subgroup includes patients with suspected microvascular angina and/or 
vasospastic angina endotypes. The burden of INOCA, particularly in women, is known to be 
significant. 
 What does this study add? 
Our cost-effectiveness analysis found that the use of adjunctive testing to identify and tailor 
treatment based on patient endotype is associated with an increase in both mean cost per 
patient and quality-adjusted life years (QALYs) gained. With an incremental cost-effectiveness 
ratio of approximately £4,500, such a clinical strategy would be highly cost-effective in a UK 
setting. 
 How might this impact on clinical practice? 
Adjunctive coronary testing would allow for the stratification of this hitherto undifferentiated 
subpopulation and the targeting of linked medical therapy. This would bring immediate 
benefits to patients in terms of an improvement in quality of life. The reduction is disease 
burden among this population would also improve the allocation of scarce health care 
resources. 
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